CYTR

CytRx Corporation Press Releases

$2.54
*  
0.02
0.79%
Get CYTR Alerts
*Delayed - data as of Nov. 25, 2014  -  Find a broker to begin trading CYTR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    CYTR Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
11/18/2014 6:00:00 AM - PR Newswire


CytRx Reports 2014 Third Quarter Financial Results
11/4/2014 6:00:00 AM - PR Newswire
▼-15.61 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium
10/30/2014 6:00:00 AM - PR Newswire
▼-11.50 % Price Change since this news event. The Volume Ratio is 0.69.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia
10/29/2014 6:00:00 AM - PR Newswire
▼-10.88 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society
10/20/2014 6:00:00 AM - PR Newswire
▼-9.29 % Price Change since this news event. The Volume Ratio is 0.97.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting
10/17/2014 6:00:00 AM - PR Newswire
▼-3.42 % Price Change since this news event. The Volume Ratio is 2.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Appoints Steven A. Kriegsman as Chairman of the Board
10/16/2014 6:00:00 AM - PR Newswire
▲2.01 % Price Change since this news event. The Volume Ratio is 1.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform
10/13/2014 6:00:00 AM - PR Newswire
▲7.17 % Price Change since this news event. The Volume Ratio is 0.85.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Gemcitabine in Patients with Metastatic Solid Tumors
10/9/2014 6:00:00 AM - PR Newswire
▲1.20 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Unexpected Passing of Chairman Max Link, PhD
10/7/2014 4:05:00 PM - PR Newswire


CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer
9/30/2014 6:00:00 AM - PR Newswire


CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer
9/29/2014 6:00:00 AM - PR Newswire


CytRx Updates Presentation Time at BioCentury's 2014 NewsMakers in the Biotech Industry Conference
9/26/2014 6:00:00 AM - PR Newswire


CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress
9/22/2014 6:00:00 AM - PR Newswire


CytRx to Present at BioCentury''s 2014 NewsMakers in the Biotech Industry Conference
9/19/2014 6:00:00 AM - PR Newswire


Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities Laws
9/16/2014 11:35:00 AM - Business Wire


Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
9/15/2014 3:23:00 PM - Business Wire


Zeldes & Haeggquist, LLP Continues Investigation of CytRx Corporation
9/15/2014 9:01:00 AM - Business Wire


CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas
9/9/2014 6:00:00 AM - Business Wire


CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference
9/5/2014 6:00:00 AM - Business Wire


CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas
9/2/2014 6:00:00 AM - Business Wire